WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 4 hours ago Drug news

Biosimilar approved by EU for treatment of breast cancer and metastatic gastric cancer

EU approves Ontruzant (trastuzumab biosimilar).

Added 4 hours ago Drug news

Novartis announces European Commission approval for Tasigna

Novartis announced that the European Commission (EC) approved Tasigna (nilotinib) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive CML

Search all news articles
 

WHAT'S ON THE HORIZON?

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 1 month ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 5 months ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 7 months ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 7 months ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Journal Abstracts

Schizophrenia relapse, patient considerations, and potential role of lurasidone.

When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available.

Added 3 days ago

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.

Background: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk...

Added 3 days ago

Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?

Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole.

Added 3 days ago

Search all journal articles
 

Latest Guidelines

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and longterm treatment of mixed states in bipolar disorder

This WFSBP guideline has been developed to supply a systematic overview of all scientific evidence pertaining to the acute and longterm treatment of bipolar mixed states in adults.

Added 12 days ago

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Evidence shows that rectal cancer is distinct from colon cancer, with different aetiologies and risk factors possibly reflecting different environmental exposures.

Added 4 years ago

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management...

Added 5 years ago

Search all guidelines
 

Latest Clinical Trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 7 days ago

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 11 days ago

Multiple Cardiac Sensors for the Management of Heart Failure (MANAGE-HF)

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

Added 1 month ago

Search all clinical trials